Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Merck |
---|---|
Information provided by: | Merck |
ClinicalTrials.gov Identifier: | NCT00565292 |
This is a study to assess the safety, efficacy, and tolerability of MK0859 in patients with primary hypercholesterolemia (large amounts of cholesterol in the blood) or mixed hyperlipidemia (high levels of LDL cholesterol, triglycerides, and low levels of HDL cholesterol in blood) This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).
Condition | Intervention | Phase |
---|---|---|
Hypercholesterolemia Hyperlipidemia |
Drug: MK0859 |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Ages Eligible for Study: | 18 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | 2007_655 |
Study First Received: | November 27, 2007 |
Last Updated: | November 27, 2007 |
ClinicalTrials.gov Identifier: | NCT00565292 |
Health Authority: | United States: Food and Drug Administration |
Metabolic Diseases Hyperlipidemias Hyperlipidemia, Familial Combined Metabolic disorder |
Combined hyperlipidemia, familial Hypercholesterolemia Dyslipidemias Lipid Metabolism Disorders |